drugset / Trial / NCT06053658
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.
Timeline
- Start
- 2024-01-05
- Primary completion
- 2026-11-01
- Completion
- 2028-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Tivozanib | Small molecule | — | Oral |